Related Experiment Video

Updated: May 18, 2026

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
11:50

Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

Chromatin organizer SATB1 as a novel molecular target for cancer therapy

Rafeeq Mir1, Saurabh J Pradhan, Sanjeev Galande

  • 1Indian Institute of Science Education and Research, Pashan. Pune 411021, India.

Current Drug Targets
|September 25, 2012
PubMed

Insights

Special AT-rich binding protein 1 (SATB1) is a global regulator of gene expression and chromatin organization. Its aberrant expression drives cancer progression by reprogramming genes involved in metastasis, making SATB1 a potential therapeutic target.

Area of Science:

  • Epigenetics and Molecular Oncology
  • Chromatin Biology
  • Gene Regulation

Background:

  • Cancer progression involves complex genetic alterations and epigenetic modifications.
  • Chromatin organization is crucial for gene transcription regulation.
  • Special AT-rich binding protein 1 (SATB1) is a global regulator linking chromatin organization and gene expression.

Purpose of the Study:

  • To review the role of SATB1 in chromatin organization and gene expression during cancer development.
  • To highlight SATB1's function as a global regulator in tumorigenesis.
  • To evaluate SATB1 as a potential molecular target for cancer therapy.

Main Methods:

  • Literature review focusing on SATB1's role in cancer.
  • Analysis of SATB1's impact on chromatin structure and gene expression.
  • Examination of SATB1's regulatory mechanisms and therapeutic potential.

Main Results:

  • SATB1 expression increases with cancer progression.
  • SATB1 reprograms genes involved in epithelial-mesenchymal transition.
  • SATB1 directly regulates key cancer-associated genes like ERRB2, MMP2, ABL1, and E-cadherin.

Conclusions:

  • SATB1 is a key regulator in cancer development, influencing chromatin organization and gene expression.
  • Understanding SATB1 regulation is crucial for developing targeted cancer therapies.
  • SATB1 presents a promising molecular target for novel cancer treatment strategies.

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...